

In re: Nicolette
USSN: 09/812,238
Filed: March 20, 2001
Page 2

AMENDMENTS

Please amend the subject application as follows:

IN THE CLAIMS:

Please amend claims 34, 35 and 42, and add new claim 43 as follows:

1-33 (canceled)

34. (currently amended) A composition comprising at least ~~[[two]]~~ one immunogenic ligands ~~ligand~~, wherein said immunogenic ~~ligands are~~ ligand is individually characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of SFDQVPFSV (SEQ ID NO:3), FSDQVPFSV (SEQ ID NO:5), ~~GVDQVPFSV (SEQ ID NO:7), MTDQVPFSV (SEQ ID NO:9), AIDQVPFSV (SEQ ID NO:11), LIDQVPFSV (SEQ ID NO:13), MVDQVPFSV (SEQ ID NO:15), and HVDQVPFSV (SEQ ID NO:17), and ITDQVPFSV (SEQ ID NO:17).~~

35. (currently amended) The composition of claim 34 or 43, further comprising a carrier.

36. (original) The composition of claim 35, wherein the carrier is a pharmaceutically acceptable carrier.

37. (original) A host cell comprising at least two immunogenic ligands, wherein said immunogenic ligands are individually characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of SFDQVPFSV (SEQ ID NO:3), FSDQVPFSV (SEQ ID NO:5), GVDQVPFSV (SEQ ID NO:7), MTDQVPFSV (SEQ ID NO:9), AIDQVPFSV (SEQ ID NO:11), LIDQVPFSV (SEQ ID NO:13), MVDQVPFSV (SEQ ID NO:15), HVDQVPFSV (SEQ ID NO:17), and ITDQVPFSV (SEQ ID NO:17).

38. (original) The host cell of claim 37, wherein the host cell is an antigen presenting cell and the immunogenic ligands are presented on the surface of the cell.

39. (original) The host cell of claim 38, wherein the antigen presenting cell is a dendritic cell.

40. (original) A composition comprising the host cell of any of claims 37 to 39 and a carrier.

41. (original) The composition of claim 40, wherein the carrier is a pharmaceutically acceptable carrier.